$1.6806
-0.0094[-0.56%]
At close: May 10
$1.6806
0[0.00%]
After Hours: 8:36AM EDT
Spero Therapeutics
(NASDAQ:SPRO)Latest News for Spero Therapeutics Stock (NASDAQ:SPRO)
Spero Therapeutics Stock (NASDAQ: SPRO)
Categories: All
Thursday, April 04, 2024
Monday, March 18, 2024
Thursday, March 14, 2024
- Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionAvi Kapoor - Mar 14, 2024, 1:38PM
- Why Robinhood Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Mar 14, 2024, 8:05AM
- Spero Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.Benzinga Newsdesk - Mar 14, 2024, 8:04AM
Wednesday, March 13, 2024
Tuesday, March 12, 2024
Wednesday, February 28, 2024
Monday, December 04, 2023
Tuesday, November 14, 2023
Monday, November 13, 2023
- 12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga Insights - Nov 13, 2023, 4:31PM
- Recap: Spero Therapeutics Q3 EarningsBenzinga Insights - Nov 13, 2023, 4:20PM
- Spero Therapeutics Q3 EPS $(0.06) Misses $(0.03) Estimate, Sales $25.47M Beat $14.97M EstimateBenzinga Newsdesk - Nov 13, 2023, 4:19PM
- Earnings Scheduled For November 13, 2023Benzinga Insights - Nov 13, 2023, 6:40AM
Friday, November 10, 2023
Wednesday, November 01, 2023
Wednesday, October 04, 2023
Tuesday, October 03, 2023
Monday, September 18, 2023
Tuesday, September 05, 2023
Monday, August 14, 2023
Thursday, August 10, 2023
Wednesday, August 09, 2023
Tuesday, August 01, 2023
Monday, July 31, 2023
- Spero Therapeutics shares are trading higher after the company announced a Special Protocol Assessment with the FDA for the Phase 3 PIVOT-PO trial of tebipenem Hbr.Benzinga Newsdesk - Jul 31, 2023, 12:51PM
- Spero Therapeutics Announces Special Protocol Assessment Agreement With FDA For Phase 3 PIVOT-PO Trial Of Tebipenem HBrBenzinga Newsdesk - Jul 31, 2023, 8:07AM